Cohen Bruce M, Murphy Beth
McLean Hospital, Belmont, MA 02478, USA.
Int J Neuropsychopharmacol. 2008 Mar;11(2):243-7. doi: 10.1017/S1461145707008073. Epub 2007 Sep 26.
Past evidence suggests that activation of kappa opiate receptors may lower mood. However, kappa agonists may also induce psychotomimetic symptoms. We tested the effects of the kappa agonist pentazocine in patients in the manic phase of bipolar disorder to determine if pentazocine might reduce symptoms of mania without worsening psychosis. In an open-label, add-on, single-day acute-dose study, ten in-patients with bipolar disorder, type 1, hospitalized for mania received two 50 mg doses of pentazocine 2 h apart. Symptoms of mania were reduced 1 h after each dose, 44% after the first dose and 41% 1 h after the second dose (F=3.69, p=0.01). No adverse effects, including psychotomimetic effects were observed or reported. Sedation was minimal. Further study of pentazocine and other kappa agonists in mania seems warranted.
过去的证据表明，κ阿片受体的激活可能会降低情绪。然而，κ激动剂也可能诱发拟精神病症状。我们测试了κ激动剂喷他佐辛对双相情感障碍躁狂期患者的影响，以确定喷他佐辛是否可以减轻躁狂症状而不加重精神病症状。在一项开放标签、附加、单日急性剂量研究中，10名因躁狂住院的1型双相情感障碍患者接受了两剂间隔2小时的50毫克喷他佐辛。每次给药后1小时，躁狂症状减轻，第一剂后减轻44%，第二剂后1小时减轻41%（F=3.69，p=0.01）。未观察到或报告包括拟精神病效应在内的不良反应。镇静作用极小。对喷他佐辛和其他κ激动剂在躁狂症中的进一步研究似乎是有必要的。
